Oppenheimer raises SiriusPoint stock price target on earnings beat

Oppenheimer raised its price target on SiriusPoint Ltd (NYSE: SPNT) to $31 from $27, citing strong Q3 2026 earnings. The company reported adjusted earnings of $0.74 per share, beating estimates, with revenue of $867.6 million. Oppenheimer updated its 2026 EPS estimate to $2.83 and introduced a 2028 estimate of $2.90, excluding one-time costs. SiriusPoint's core combined ratio remained steady at 90.1%.

Original reporting
Published Nov 9, 2026, 4:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 4:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SPNT
Bullish
high confidence
Mentioned
$SPNT
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SPNTBullishMed
01

Why it matters

The earnings beat and higher target suggest the stock may rally, but investors should monitor core loss ratios and upcoming portfolio transfers.

02

Market read

Earnings beat and analyst target raise provide fresh bullish catalyst for SPNT.

03

What to watch

Potential exposure to future catastrophe losses not reflected in the current guidance.

Relevance 7/10Novelty 8/10Timing: post‑earnings today

Background

SiriusPoint reported Q3 2026 adjusted EPS of $0.74 versus $0.64 consensus and revenue of $867.6 million, prompting Oppenheimer to lift its price target.

Company-level read

Ticker impact

$SPNTBullishHigh confidence
Context

Oppenheimer raised its price target on SiriusPoint to $31 after the company reported a Q3 earnings beat.

Expected impact

upward pressure as investors price in stronger earnings and higher guidance.

Evidence & confidence

The price target increase from $27 to $31 reflects Oppenheimer's view that the stock is undervalued and earnings beat supports upside.

Market effects

Positive earnings and target raise may lift other specialty insurers.

Limited to U.S. insurance sector.

Minimal global impact.

Counterpoint

The target raise could be premature if underlying loss ratios deteriorate.

Key entities

  • SiriusPoint Ltd

    Specialty insurer listed on NYSE.

  • Oppenheimer

    Equity research firm that raised the price target.

Related articles

$SPNTMed

SiriusPoint Q3 Earnings Call Highlights

SiriusPoint (SPNT) reported Q3 earnings, with insurance premiums up 20% and reinsurance down 6%. The company expects to complete a transaction by Q4 2023 or Q1 2024, with $74M remaining for share repurchases. Core underwriting income rose 22% to $202M. SiriusPoint plans to restructure its reporting segments and anticipates modest growth in 2027.

$SPNTMedAI 8/10

SiriusPoint (SPNT) Q3 2026 Earnings Call Transcript

SiriusPoint (SPNT) reported Q3 2026 earnings, highlighting 20% growth in insurance and services, a core combined ratio of 90.1%, and an operating return on equity of 17.6%. The company also announced a loss portfolio transfer agreement to reduce legacy runoff exposures, freeing up over $200 million in capital. Year-to-date, insurance and services grew by 14%, with a core combined ratio of 90.1% and an operating return on equity of 15.8%.

MedAI 8/10

SiriusPoint run-off deal expected to release $200m

SiriusPoint announced a deal to release $200M in capital via a loss portfolio transfer with RiverStone. Q3 net income was $87M, down from $90.7M YoY, but operating net income rose to $103.2M. Core gross written premiums grew 13.7% to $990.6M, with Insurance & Services driving growth. CEO Scott Egan highlighted 17.6% operating returns on equity, exceeding targets.